Company Updates
25 April 2024
Investor Q&A with Steven Yatomi-Clarke
In this session Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke discussed the key highlights:
- An update on Prescient’s strategy and upcoming milestones, with a focus on PTX-100.
- The journey of value creation for biotech companies, and why Prescient is on the cusp of a significant inflection point.
- Why the data from their PTX-100 Phase 1b trial is so promising.
- How the development pathway for PTX-100 could be considerably shorter and cheaper than conventional drug development paths.
- How their $18m cash position allows them to go deep into a Phase 2 trial.
Recorded on 25th March 2024 at 12pm (AEDT).
COMPANY UPDATES
View all
Company Updates
22 April 2024
Nicolab Investor Briefing
Company Updates
18 April 2024
Far East Gold Investor Briefing
Company Updates
18 April 2024
Joyned Q&A Update
Open investments
View all
Asian Battery Metals (AZ9)
Request Prospectus
Investment Type:
Our Role:
Zetaris
Request Offer Docs Investment Type:
Our Role:
upcoming events
View all
Connecting quality investors and innovative companies to facilitate mutual wealth creation with trust and transparency
Speak to an Adviser
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.